Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

The FDA is about to make it a lot harder to get cheap weight-loss drugs Jessica DeBenedetto has only been on compounded tirzepatide for a couple of weeks, but she already feels like it's a life ...

All PCOS patients met all three criteria of the revised 2003 Rotterdam European Society of Human Reproduction and Embryology (ESHRE)/American Society of Reproductive Medicine (ASRM) PCOS Consensus ...

At least nine patients using the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and tirzepatide developed ophthalmic complications, of whom seven had nonarteritic anterior ischemic ...

Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials. OSA is a prevalent ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular ...

Mounjaro (tirzepatide) is a prescription drug used to help manage blood sugar levels in adults with type 2 diabetes. Mounjaro comes as an injection that’s given under your skin. This medication ...

She takes compounded tirzepatide for weight loss. In 2020, Chanel Robinson’s polycystic ovary syndrome (PCOS) was flaring. She developed seborrheic dermatitis and she felt like her health was on ...

Medications like semaglutide and tirzepatide have gained significant attention for their impressive weight-loss effects, but they do much more than just helping you shed pounds. Let’s dive into ...

Mounjaro is one brand name for the drug tirzepatide from the pharmaceutical manufacturer Eli Lilly. It’s also FDA-approved to help those with type 2 diabetes manage blood sugar and prescribed ...

The injected Zepbound® produced a total of 38 adverse events across the study group of 9 persons, whereas the oral DehydraTECH-tirzepatide only produced 20 adverse events, a reduction of 47%.